Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed

NEW YORK, January 14, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), GW Pharmaceuticals plc (NASDAQ: GWPH), Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Insmed Incorporated (NASDAQ: INSM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On January 8, 2014, Johnson & Johnson's subsidiary Janssen Pharmaceutical Companies reported that it has submitted a Citizen Petition to the U.S. Food and Drug Administration (FDA) regarding naming of biosimilars. According to the Company, in its petition it has asked the agency to require biosimilars to bear nonproprietary names that are similar to, but not the same as, those of their reference products or of other biosimilars. According to the Company, the petition states that distinguishable names are essential for enhancing patient safety and to ensure effective pharmacovigilance. Commenting on the update, Jay P. Siegel, M.D., Chief Biotechnology Officer and Head, Scientific Strategy and Policy at Johnson & Johnson, stated, "Ensuring biosimilars bear distinguishable names is of critical importance for patient safety. Names that are similar but not the same will appropriately reflect the legal and scientific reality that biosimilars are similar to but not the same as their reference products or other biosimilars." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

GW Pharmaceuticals plc Research Report

On January 8, 2014, GW Pharmaceuticals plc (GW Pharmaceuticals) announced the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the Nasdaq Global Market. According to the Company, it will issue 2,441,110 ADSs on the Nasdaq Global Market at a price of $36.00 per ADS, raising gross proceeds of $87.9 million, before underwriting discount, commissions and offerings expenses deductions. GW Pharmaceuticals also reported that it has granted the underwriters a 30-day option to purchase up to an additional 366,165 ADSs at the offering price. According to the Company, the offering is expected to close on January 14, 2014. GW Pharmaceuticals further named Morgan Stanley & Co. LLC and Cowen and Company, LLC as joint book-running managers for the offering, while Piper Jaffray & Co. and Canaccord Genuity Inc. are acting as lead manager and co-lead manager, respectively. The Full Research Report on GW Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  

http://www.analystscorner.com/r/full_research_report/26a5_GWPH

--

Conatus Pharmaceuticals Inc. Research Report

On January 9, 2014, Conatus Pharmaceuticals Inc.'s stock significantly increased 57.05% to $9.80. For the past three trading day session, the Company's stock edged up 60.66%, compared to the Dow Jones Industrial Average Index, which gained 0.12% during the same three-day trading period. The Full Research Report on Conatus Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/415c_CNAT

--

Chelsea Therapeutics International Ltd. Research Report

On January 9, 2014, Chelsea Therapeutics International Ltd.'s stock gained 10.31% to $3.53. The Company's stock gained 2.92% over the past three trading days, compared to the Nasdaq composite Index which increased 1.03% during the same trading period. The Full Research Report on Chelsea Therapeutics International Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c6ad_CHTP

--

Insmed Incorporated Research Report

On January 9, 2014, Insmed Incorporated's (Insmed) stock gained 6.01%, closing the day at $19.58. Over the previous three day trading session, Insmed shares increased 8.48%, compared to the Dow Jones Industrial Average Index which gained 0.12% during the same three-day trading period. The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9c5b_INSM

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

1. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
2. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
3. For any urgent concerns or inquiries, please contact us at [email protected].
4. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner